Open AccessOnce-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study
Author(s) -
Satish Modi,
Robert Lehmann,
Thomas R. Walters,
Raymond Fong,
William C. Christie,
Lawrence Roel,
David A. Nethery,
Dana Sager,
Alexis Tsorbatzoglou,
Bo Philipson,
Carlo Enrico Traverso,
Harvey Reiser
Publication year - 2013
Publication title -
journal of cataract and refractive surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.678
H-Index - 142
eISSN - 1873-4502
pISSN - 0886-3350
DOI - 10.1016/j.jcrs.2013.07.042
Subject(s) - medicine , cataract surgery , randomized controlled trial , surgery , clinical endpoint , ophthalmology , confidence interval , anesthesia
To evaluate once-daily nepafenac 0.3% to prevent and treat ocular pain and inflammation after cataract surgery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom